Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1

Biochemical and Biophysical Research Communications

Volumn 400, Issue 4, 2010, Pages 619-624

  Vanderslice, Peter ^a   Woodside, Darren G ^a   Caivano, Amy R ^a   Decker, E Radford ^a   Munsch, Christy L ^a   Sherwood, Sidney J ^a   LeJeune, Wanda S ^a   Miyamoto, Yuko J ^b   McIntyre, Bradley W ^b   Tilton, Ronald G ^a   Dixon, Richard A F ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell trafficking; Eosinophils; Inflammation; Integrin

Indexed keywords

ALPHA7 INTEGRIN; ANTIINFLAMMATORY AGENT; EPITOPE; MONOCLONAL ANTIBODY; TBC 3486; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; DRUG ACTIVITY; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYPERSENSITIVITY; INFLAMMATION; INTEGRIN ALPHA4BETA1; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; PROTEIN CONFORMATION; PULMONARY EOSINOPHILIA; T-LYMPHOCYTES; THIOPHENES; UREA;

ANIMALIA;

EID: 77957280268     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.114     Document Type: Article

References (26)

1. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
2. Luster A.D., Alon R., von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
3. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
4. Henderson W.R., Chi E.Y., Albert R.K., Chu S.J., Lamm W.J., Rochon Y., Jonas M., Christie P.E., Harlan J.M. Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest. 1997, 100:3083-3092.
5. Engelhardt B., Laschinger M., Schulz M., Samulowitz U., Vestweber D., Hoch G. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J. Clin. Invest. 1998, 102:2096-2105.
6. Teixeira M.M., Robinson M.K., Shock A., Hellewell P.G. Alpha(4) integrin-dependent eosinophil recruitment in allergic but not non-allergic inflammation. Br. J. Pharmacol. 2001, 132:596-604.
7. Podolsky D.K., Lobb R., King N., Benjamin C.D., Pepinsky B., Sehgal P., deBeaumont M. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J. Clin. Invest. 1993, 92:372-380.
8. Picarella D., Hurlbut P., Rottman J., Shi X., Butcher E., Ringler D.J. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J. Immunol. 1997, 158:2099-2106.
9. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., Spehlmann M.E., Rutgeerts P.J., Tulassay Z., Volfova M., Wolf D.C., Hernandez C., Bornstein J., Sandborn W.J. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007, 132:1672-1683.
10. Takagi J., Petre B.M., Walz T., Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002, 110:599-611.
11. Leone D.R., Giza K., Gill A., Dolinski B.M., Yang W., Perper S., Scott D.M., Lee W.C., Cornebise M., Wortham K., Nickerson-Nutter C., Chen L.L., LePage D., Spell J.C., Whalley E.T., Petter R.C., Adams S.P., Lobb R.R., Pepinsky R.B. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 2003, 305:1150-1162.
12. Yang J.T., Rayburn H., Hynes R.O. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 1995, 121:549-560.
13. Spence S., Vetter C., Hagmann W.K., Van Riper G., Williams H., Mumford R.A., Lanza T.J., Lin L.S., Schmidt J.A. Effects of VLA-4 antagonists in rat whole embryo culture. Teratology 2002, 65:26-37.
14. Crofts F., Rohatagi S., Pino M., DeLise B., Zhang J., Nguyen M., Guittin P., Barbellion S., Brunel P., Hofmann T., Schmidt J., Wong M., Lockey P., Lerman S., Clark R. Critical period for a teratogenic VLA-4 antagonist: developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists. Birth Defects Res. B: Dev. Reprod. Toxicol. 2004, 71:69-79.
15. R.J. Biediger, V.O. Grabbe, G.W. Holland, J.M. Kassir, T.P. Kogan, S. Lin, R.V. Market, B.G. Raju, I.L. Scott, C. Wu, N,N-Disubstituted amides that inhibit the binding of integrins to their receptors, U.S. Patent No. 6, 194,448, Texas Biotechnology Corporation, US, 2001.
16. Woodside D.G., Kram R.M., Mitchell J.S., Belsom T., Billard M.J., McIntyre B.W., Vanderslice P. Contrasting roles for domain 4 of VCAM-1 in the regulation of cell adhesion and soluble VCAM-1 binding to integrin alpha4beta1. J. Immunol. 2006, 176:5041-5049.
17. McIntyre B.W., Woodside D.G., Caruso D.A., Wooten D.K., Simon S.I., Neelamegham S., Revelle J.K., Vanderslice P. Regulation of human T lymphocyte coactivation with an alpha4 integrin antagonist peptide. J. Immunol. 1997, 158:4180-4186.
18. Das A.M., Flower R.J., Hellewell P.G., Teixeira M.M., Perretti M. A novel murine model of allergic inflammation to study the effect of dexamethasone on eosinophil recruitment. Br. J. Pharmacol. 1997, 121:97-104.
19. Ni H., Li A., Simonsen N., Wilkins J.A. Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. J. Biol. Chem. 1998, 273:7981-7987.
20. Bednarczyk J.L., Szabo M.C., Wygant J.N., Lazarovits A.I., McIntyre B.W. Identification of a combinatorial epitope expressed by the integrin alpha 4 beta 1 heterodimer involved in the regulation of cell adhesion. J. Biol. Chem. 1994, 269:8348-8354.
21. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 2001, 7:687-692.
22. Davis L.S., Oppenheimer-Marks N., Bednarczyk J.L., McIntyre B.W., Lipsky P.E. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol. 1990, 145:785-793.
23. Koo G.C., Shah K., Ding G.J., Xiao J., Wnek R., Doherty G., Tong X.C., Pepinsky R.B., Lin K.C., Hagmann W.K., Kawka D., Singer I.I. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am. J. Respir. Crit. Care Med. 2003, 167:1400-1409.
24. Walsh G.M., Symon F.A., Lazarovils A.L., Wardlaw A.J. Integrin alpha 4 beta 7 mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin. Immunology 1996, 89:112-119.
25. Bazan-Socha S., Bukiej A., Pulka G., Marcinkiewicz C., Musial J. Increased expression of collagen receptors: alpha1beta1 and alpha2beta1 integrins on blood eosinophils in bronchial asthma. Clin. Exp. Allergy 2006, 36:1184-1191.
26. Brandt E.B., Zimmermann N., Muntel E.E., Yamada Y., Pope S.M., Mishra A., Hogan S.P., Rothenberg M.E. The alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. Clin. Exp. Allergy 2006, 36:543-553.